Who owns Eton Pharmaceuticals Inc?
- Ticker: ETON
- CUSIP Number: 29772l108
Tip: Access positions for across all investors
Analyze quarterly positions in Eton Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Eton Pharmaceuticals stock
Who bought or sold Eton Pharmaceuticals Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Opaleye Management | 2.4M | $9.2M | -3% | Mar 2024 |
|
| Vanguard Group | 1.0M | $3.9M | 0% | Mar 2024 |
|
| Acuitas Investments | 580k | $2.2M | 18% | Mar 2024 |
|
| Westside Investment Management | 574k | $2.2M | 2% | Mar 2024 |
|
| Paradigm Capital Management | 300k | $1.1M | 0% | Mar 2024 |
|
| BlackRock | 283k | $1.1M | -1% | Mar 2024 |
|
| Bridgeway Capital Management | 253k | $950k | -7% | Mar 2024 |
|
| Geode Capital Management | 234k | $878k | 8% | Mar 2024 |
|
| Susquehanna International | 223k | $838k | 902% | Mar 2024 |
|
| Parkman Healthcare Partners | 199k | $747k | 21% | Mar 2024 |
|
| Acadian Asset Management | 156k | $585k | 61% | Mar 2024 |
|
| Goldman Sachs Group | 119k | $446k | 100% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 97k | $363k | 66% | Mar 2024 |
|
| Essex Investment Management | 79k | $295k | 0% | Mar 2024 |
|
| Bank of New York Mellon | 75k | $279k | -6% | Mar 2024 |
|
| Northern Trust | 61k | $229k | 63% | Mar 2024 |
|
| Squarepoint Ops | 49k | $184k | -23% | Mar 2024 |
|
| Qube Research & Technologies | 45k | $167k | 838% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 39k | $147k | -9% | Mar 2024 |
|
| William Blair $ Company | 37k | $139k | 0% | Mar 2024 |
|
| Two Sigma Investments | 32k | $119k | -39% | Mar 2024 |
|
| Citadel Advisors | 29k | $107k | 20% | Mar 2024 |
|
| Jane Street | 23k | $87k | 25% | Mar 2024 |
|
| Jpmorgan Chase & Co | 19k | $72k | 100% | Mar 2024 |
|
| Two Sigma Advisers | 18k | $66k | 62% | Mar 2024 |
|
| CHICAGO TRUST Co NA | 17k | $63k | 0% | Mar 2024 |
|
| XTX Topco | 14k | $53k | 18% | Mar 2024 |
|
| Charles Schwab Investment Management | 13k | $50k | 0% | Mar 2024 |
|
| Heron Bay Capital Management | 12k | $50k | 4% | Dec 2023 |
|
| Quantum Private Wealth | 12k | $43k | 0% | Mar 2024 |
|
| Financial Advisors Network | 11k | $47k | 0% | Dec 2023 |
|
| Dimensional Fund Advisors | 11k | $40k | 0% | Mar 2024 |
|
| Raymond James & Associates | 10k | $38k | 1% | Mar 2024 |
|
| Tower Research Capital | 7.6k | $29k | 548% | Mar 2024 |
|
| UBS Group | 2.0k | $7.4k | -48% | Mar 2024 |
|
| Wells Fargo & Company | 1.4k | $5.3k | 728% | Mar 2024 |
|
| Lazard Asset Management | 1.1k | $4.0k | 100% | Dec 2023 |
|
| Plante Moran Financial Advisors | 1.0k | $3.8k | 0% | Mar 2024 |
|
| Royal Bank of Canada | 765.00 | $3.0k | -71% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 350.00 | $1.3k | 0% | Mar 2024 |
|
| Morgan Stanley | 38.00 | $143.001600 | -60% | Mar 2024 |
|
| Lindbrook Capital | 4.00 | $15.000000 | 0% | Mar 2024 |
|
Who sold out of Eton Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Eudaimonia Asset Management | Sep 2023 | 257k | $1.1M |
| Ameriprise Financial | Sep 2023 | 187k | $778k |
| Bank Of Montreal | Dec 2023 | 30k | $142k |
| Victory Capital Management | Dec 2023 | 28k | $123k |
| Stratos Wealth Partners | Dec 2023 | 27k | $118k |
| Bailard | Dec 2023 | 23k | $99k |
| Jump Financial | Sep 2023 | 21k | $88k |
| Millennium Management | Dec 2023 | 20k | $89k |
| Virtu Financial | Dec 2023 | 13k | $57k |
| Citigroup | Dec 2023 | 2.2k | $9.8k |
| CFG Asset Management | Dec 2023 | 1.0k | $4.4k |
| Goss Wealth Management | Sep 2023 | 175.00 | $729.995000 |
| Bank of America Corporation | Dec 2023 | 28.00 | $121.998800 |